

Sponsored by MSD

Advances in Gastrointestinal Cancers: A Focus on Immuno-Oncology (IO)

CHAIR

Toh Han Chong

Deputy Medical Director
National Cancer Centre Singapore
Associate Professor at the
Cancer & Stem Cell Biology
Program and SingHealth-Duke
Global Health Institute
Duke-NUS
Singapore

FACULTY

Kong Hwai Loong

Medical Oncologist
Icon Cancer Centre
Adjunct Associate Professor
National University of Singapore
Singapore

Andrew Zhu

Director
Jiahui International
Cancer Center
Director Emeritus,
Liver Cancer Research
Massachusetts General Hospital
Cancer Center
Professor of Medicine
Harvard Medical School
Cambridge, Massachusetts, USA

Yelena Janjigian

Chief, Associate Attending
Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering
Cancer Center
New York, New York, USA

Ken Kato

Chief
Department of Head and Neck
Medical Oncology
Head Physician
Department of Gastrointestinal
Medical Oncology
National Cancer Center Hospital
Tokyo, Japan

Virtual Symposium

Saturday, 21 November 2020

12:00 – 13:30 (SGT) • Channel 6

Chair: Toh Han Chong (Singapore)

AGENDA

12:00 – 12:10	Overview of the GI Cancers Treatment Landscape in Asia <i>Toh Han Chong</i>
12:10 – 12:25	Redefining the Treatment Landscape in MSI-H Cancers With IO Monotherapy: CRC and Non-CRC <i>Kong Hwai Loong</i>
12:25 – 12:40	Rapidly Changing Treatment Landscape of HCC: Role of IO Monotherapy and in Combination <i>Andrew Zhu</i>
12:40 – 12:55	Evolving Role of Biomarker-Guided Treatment Options in 1L Metastatic Gastric Cancer <i>Yelena Janjigian</i>
12:55 – 13:10	Managing the Esophageal Cancer Patient in the Immuno-Oncology Era <i>Ken Kato</i>
13:10 – 13:30	Live Q&A <i>All</i>

This symposium is fully funded and organised by MSD and MSD product may be mentioned. Refer to your local Prescribing Information before prescribing, as it may differ between countries. Adverse events should be reported as per your local guidance.

This program is not intended for health care professionals who practice in, are licensed to practice in, or reside in the U.S., its territories, or Puerto Rico.

Agenda may be subject to change pending speaker confirmation

